Stelerix Web Blog Knowledge at your Fingertips

26Jan/110

Distribution Hurdles.

I caught up with Tushar Barad, Owner of Applied Biosciences, based in Mumbai, to ask him about some of the challenges and successes in his role. I'm editing the interview into bite-size portions, for now. I will compile on a page in the main site, but wanted to publish these wise words as quickly as possible. Here is the first excerpt. I hope you enjoy, as always, please leave your comments.

Posted by Jeff

14Dec/100

After Hours Activities

Given tomorrow's big visit, and amidst all the questions and comparisons between India and China, this article proves timely and insightful. It's encouraging to see a focus on trade developing, as the two colossal markets try their best to get comfortable in a sea of shifting economic tides. The look into what products are exchanged between the two countries is telling, as well.

While it is touched on here that a free trade agreement might not be realistic at this point in time, headway is nevertheless being made. A comment by Ajay Sahai, director general of the Federation of Indian Export Organizations, caught our interest when he mentioned that Indian pharma exports to China are hindered by an inflexible Yuan which dictates an artificial price exporters can't match, and a regulatory approval process that can take 4 times longer than most other countries.

Fierce Pharma highlights intriguing and proactive developments taken by Indian regulatory authorities.

On an unrelated note, if you haven't seen this story about the Berlin Patient, you have absolutely got to check it out. That's all for now.

Posted by Jeff

14Dec/100

Merger Mondays

When you are focused, it is exciting to see dynamic happenings. Here's what I mean:

Today, Lincoln Pharmaceuticals Ltd. further invests in India after initial success in accelerating wound healing. The company sites cost effectiveness and affordability of care as a goal. Interesting.

Watson Pharmaceuticals is also actively looking to get into the India, although plans won't materialize for 18 months.

Reckitt Benckiser will acquire Paras Pharma, and it's diverse array of over the counter consumer products. Analysts noted the price as high, but our own research has continually concluded that a long term outlook and effective logistic and expectation management can lead to very worthwhile ROI.

Posted by Jeff

7Dec/100

Clinical Trial Outsourcing Resources

In light of this recent Vanity Fair piece, and given our own interest, we will talk actively and transparently about what we’re doing, how we’re getting our information and where we can improve.

Besides, if our goal is to share knowledge, openly exploring our resources with you loyal readers will surely be of benefit, and well within the “Knowledge at Your Fingertips” mandate. It’s important to remember the mandate, we’d say. To that end, we’ll share the best of our curatorial efforts, compiling and creating quality content.

Our particular area of interest, these days? Clinical trial outsourcing. Here’s what we found:

An incredibly thorough SlideShare presentation by Robert M Califf, Vice-Chancellor for Clinical Research at Duke Translational Medicine Institute, “Unresolved issues in the Globalization of Clinical Trials.”

Further on the theme of SlideShare, “Clinical Trials: Overview and Opportunities” by Dr. Kumud Sarin, from the Bioinformatics Institute of India, is a colorful yet effective background for anyone looking to familiarize themselves with the ins and outs of clinical trials. From ethical best practice, industry career prospects, and a compelling case for investing in India, it’s all there.

Finally, this quick read gives an overview of clinical trials in emerging markets, and highlights why India is critical for those who want to optimize such operations. We were also happy to see that it highlighted the need for emergency infrastructure in emerging markets, especially when first-in-man studies are being conducted.

Posted by Jeff

http://www.vanityfair.com/politics/features/2011/01/deadly-medicine-201101
29Nov/100

Analyzing Answers

We've been particularly busy over the last month. We have been working hard to directly engage over 1400 pharmaceutical industry decision makers in 12 countries.

Our primary focus these days is on the unparalleled opportunity in India. Our valued respondents have provided validated input highlighting not only the potential for success, but also the high-risk areas that must be attended to with the utmost responsibility. It's a complex marketplace which can be leveraged in a veritable plethora of ways. We hope that the results of our ongoing end-user engagement will provide you some context to help decide how India will best fit into your strategic roadmap.

We're in the process of analyzing this data. We have a lot more to sort through; but so far,  it looks promising. We'll share the end results with you very soon.

We fervently believe that input from relevant stakeholders around the globe is a key ingredient in creating successful knowledge-based solutions.

follow: @stelerix

Posted by Jeff

15Nov/100

Unlocking India – Upcoming Webinar Series

Thanks for stopping by. Here is what we are focusing on, currently. Each blurb is a 2-3 hour webinar. After you read it, can you let us know what specifically you would be most interested in hearing about? Please?

“Mr. Nitin Parab assembles a trio of key opinion leaders for an interactive, case-study driven discussion. Achieve seamless regulatory compliance and ensure accelerated approval and market penetration as Nitin works with leading USFDA and EDQM experts.”

“Dr. Varma is a key player in a wide network of experts, who consistently craft successful contract-manufacturing agreements, and reap the benefits. Partake in an interactive discussion. Overcome common hurdles. Cut costs, drastically. Create effective and scalable strategic alliances with qualified local partners.”

“Hear from the architect of a record global licensing and distribution deal. Mr. Alok Kumar explains how to thrive in a fragmented market, wherein 10,000 companies vie for 70% of market share. He is the undeniable expert, when it comes to implementing immensely profitable alliances.”

“Dr. Anantharaman and three of his leading industry peers will provide an in-depth analysis of what is required for maximum market access. Specific emphasis will be placed on how scientific and evidence-based marketing strategies have been used as a significant driver of market share in a fragmented and tumultuous Indian market”

Thanks for reading. So, what do you think?

Tell us how we can refine this content. What information would make a webinar worth your while? Think about it! We can do this for you!

Answer here.

To request more information about attending these webinars, scalable advertising, or to subscribe to our newsletter, email: info@stelerix.com

Follow: @stelerix